With the help of Marker’s technology, a population of T-cells attacks multiple cancer targets and works to activate a patient’s immune system to trigger anti-tumor activity.
Company to host business update call and webcast today at 5:00 p.m. EDT
Marker Therapeutics announces business update conference call and webcast on Thursday, March 28th.
DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.